Horizon 2020 projects
The Horizon 2020 programme of the European Commission is of key importance for the funding of RIVM's international collaboration. Horizon 2020 succeeds the Seventh Framework Programme and is the biggest EU Research and Innovation programme in Europe. Horizon 2020 stimulates research and innovation in the EU. The Horizon 2020 work programme comprises of several pillars and various thematic sections. RIVM is mainly involved in projects within the societal challenges, but our institute is also involved in projects in other pillars. Within the Societal Challenges RIVM focuses mainly on Health, Climate Action and Environment, Secure Societies, and Food Security.
Together with partners all over Europe, RIVM was involved in over 70 projects funded by the 7th Framework Programme for Research and Technological Development, FP7. This EU programme ran from 2007 until 2013 and awarded grants to co-finance research, technological development and demonstration projects. Grants ware determined on the basis of calls for proposals and a peer review process. RIVM is still in progress on several projects.
Innovative Medicines Initative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. IMI launches research and/or training projects every year. Project participants are recruited through open and competitive calls for research proposals. The selection of the winning proposals is based on independent peer review. RIVM is a partner in several IMI financed projects.
Basically, a Joint Action is a group of coherent activities on a specific topic, which is jointly funded by the European Commission and the EU Member States who have decided to participate in it. Joint Actions have a clear EU added value and are co-financed either by competent authorities that are responsible for health in the Member States or in the third countries participating in the Programme, or by public sector bodies and non-governmental bodies mandated by those competent authorities. As a result, a Joint Action also provides outcomes that offer benefits on the national level.
RIVM has been involved in numerous international projects. On this page we present a selection of completed projects.
|Third Health Programme projects|
|EVENT and DIVINE-NET|